Efeitos do Buflomedil em pacientes submetidos à revascularização arterial de membros inferiores

• Ano de defesa: 2001
• Autor(a) principal: Aquino Filho, Rubens de
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Uberlândia; Brasil; Programa de Pós-graduação em Ciências da Saúde
• Palavras-chave em Português: CPK; Metabolismo energético da célula; CNPQ::CIENCIAS DA SAUDE
• Link de acesso: https://repositorio.ufu.br/handle/123456789/27968; http://doi.org/10.14393/ufu.di.2001.29

The ischemic process consists in an extremely harmfiil event to the issues. Cellular injuries having a variable degree can result from this ischemia and these injuries may cause their death. It is known that the ischemic process starts with the partial or total reduction of the blood supply and goes on for a certain period of time even after the arterial blood flow restoration. This research was done in order to analyze the buflomedil hydrochloride effects in the transitory ischemic during the peripheral arterial revascularization in patients who experienced the chronic ischemic syndrome. Twenty-one patients carrying the low members chronic ischemic syndrome have been studied (Ilb Fontaine phase),with the superficial femoral artery entire occlusion, and refilling in popliteal artery above knee joint, having arteriosclerotic etiology. The patients have been selected in Angiology clinicai unit of the Medicine College Hospital belonging to the Federal University in Uberlândia (FMUFU), from January 1997 to December 1999. Thirteen was female (61,90%), and eight male (38,10%), with age ranging from 62 to 88 years (an average of 70,54 years old). The arteriosclerotic process diagnosis as well as the obstruction standard were made by the clinic evaluation and arteriographic finding. The patients were divided into two groups: Group I (femoropopliteal revascularization and buflomedil hydrochloride); Group II (isolated femoropopliteal revascularization). The CPK and cutaneous temperature have been used to evaluate a possible Protective effect caused by the buflomedil hydrochloride. The CPK dosage and cutaneous temperature measure occurred in the following moments: pre-operation, first hour, sixth hour, twelfth hour, twenty-fourth hour, forty-eight hour and seventy- second hour post-revascularization. The group I presented higher temperatures when compared to group II in the various moments, which were analyzed, although this difference wasn't statistically signifícant. Differently from what was noticed in the cutaneous temperature, the CPK leveis found in group I, were lower than in group II and this difference was statistically signifícant. Our findings lead us to the following conclusions: 1 - Buflomedil hydrochloride seems to cause an additional tissue protection against transitory ischemia that appears as a consequence of the peripheraí arterial revascularization surgery. 2 - We can assert that buflomedil hydrochloride caused additional benefits in patients who experienced the peripheraí arterial revascularization, possibly for having decreased the cellular injuries, caused by the transitory ischemia during the surgery. Thus Buflomedil can be recommended as a co adjuvant in those patients who will experience the peripheraí arterial revascularization.